Needham Maintains Buy on Definium Therapeutics, Raises Price Target to $66
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Needham analyst Ami Fadia maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $50 to $66.
Needham analyst Ami Fadia maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $50 to $66.